Literature DB >> 21816675

Energy balance regulation by endocannabinoids at central and peripheral levels.

Carmelo Quarta1, Roberta Mazza, Silvana Obici, Renato Pasquali, Uberto Pagotto.   

Abstract

Dysregulation of the endocannabinoid system (ECS) is a universal and, perhaps, causative feature of obesity. Central nervous system (CNS) circuits that regulate food intake were initially believed to be the targets for dysregulation. However, it is increasingly evident that endocannabinoids affect food intake, energy expenditure and substrate metabolism by acting on peripheral sites. Cannabinoid type 1 receptor (CB1r) antagonists can effectively treat obesity and associated metabolic alterations but, unfortunately, cause and exacerbate mood disorders. Drugs restricted to act on peripheral CB1rs might be safer and more effective, retaining the anti-obesity effects but lacking the adverse neurodepressive reactions. This review summarizes the emerging roles of the ECS in energy balance and discusses future pharmacological approaches for developing peripherally restricted CB1r antagonists.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816675     DOI: 10.1016/j.molmed.2011.05.002

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  38 in total

1.  Circadian rhythm of circulating levels of the endocannabinoid 2-arachidonoylglycerol.

Authors:  E C Hanlon; E Tasali; R Leproult; K L Stuhr; E Doncheck; H de Wit; C J Hillard; E Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 2.  The thrifty lipids: endocannabinoids and the neural control of energy conservation.

Authors:  Nicholas V DiPatrizio; Daniele Piomelli
Journal:  Trends Neurosci       Date:  2012-05-22       Impact factor: 13.837

Review 3.  New insights on the role of the endocannabinoid system in the regulation of energy balance.

Authors:  B Gatta-Cherifi; D Cota
Journal:  Int J Obes (Lond)       Date:  2015-09-16       Impact factor: 5.095

Review 4.  Monoacylglycerol lipase - a target for drug development?

Authors:  C J Fowler
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.

Authors:  Mayank Kumar Sharma; Prashant R Murumkar; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

6.  Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.

Authors:  C E Moss; W J Marsh; H E Parker; E Ogunnowo-Bada; C H Riches; A M Habib; M L Evans; F M Gribble; F Reimann
Journal:  Diabetologia       Date:  2012-08-08       Impact factor: 10.122

Review 7.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

Review 8.  Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.

Authors:  Gernot F Grabner; Robert Zimmermann; Rudolf Schicho; Ulrike Taschler
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

9.  Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.

Authors:  Dai Lu; Rachel Dopart; Debra A Kendall
Journal:  Cell Stress Chaperones       Date:  2016-01       Impact factor: 3.667

Review 10.  The unrelenting fall of the pharmacological treatment of obesity.

Authors:  Guido Di Dalmazi; Valentina Vicennati; Renato Pasquali; Uberto Pagotto
Journal:  Endocrine       Date:  2013-05-16       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.